FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement

 
• By Brenda Sandburg

Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.

merger horizon
Federal Trade Commission reaches consent order allowing Amgen's acquisition of Horizon Therapeutics • Source: Shutterstock

More from Legal & IP

More from Pink Sheet